Background: Leadless pacing is generally performed from a femoral approach. However, the femoral route is not always available. Until now, data regarding implantation using a jugular approach other than a single-case report were lacking.
INTRODUCTION
Leadless pacemaker (PM) implantation has until now been performed from the femoral vein with the exception of a single case via the jugular vein, published by Kolek et al. 1 These authors described a patient who had a caval filter for prevention of thromboembolism, and in whom they successfully implanted a leadless PM (Micra, Medtronic, Dublin, Ireland) using the internal jugular vein. In the two cases described below, where femoral approach was not possible, the jugular approach was used instead. Based on this favorable experience, the jugular This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. approach was used more frequently. This study describes 19 patients who underwent leadless PM implantation from the internal jugular vein.
Case 1
The index patient was a 58-year-old female patient, who presented with a highly symptomatic longstanding persistent atrial fibrillation 2 ). Excellent sensing and pacing threshold values were obtained.
Case 2
The Due to the previously unsuccessful implantation attempt, a second conventional implant attempt was rejected and a leadless pacing system was chosen. A lack of support from femoral access was anticipated due to the severely dilated atrium. In addition, the presence of a tricuspid annuloplasty ring was thought to cause axial catheter pressure to be diverted superiorly instead of to the right ventricular wall when using the femoral route. So, a straighter approach to the right ventricle from the jugular vein was used. Despite the severely dilated right atrium, the leadless PM was implanted without any complications and excellent sensing and pacing threshold values were obtained.
METHODS
Case files of all patients who underwent leadless PM implantation at our center were retrospectively analyzed. The study was reviewed by the regional medical ethical committee. All patients consented to their case records being reviewed and consented to use of the data for publication. A consistent implant technique was used in all cases.
Implant procedure
In all cases, a central approach to the jugular vein was used as described by Daily et al. 2 Both the sternal and clavicular head of the sternocleidomastoid muscle were identified. After the skin was appropriately disinfected and the patient draped, lidocaine 1% was used to infiltrate the skin between the two heads of the sternocleidomastoid muscle using a 22-gauge needle. Then the internal jugular vein was entered with the 22-gauge needle, which was left in place as a landmark. Next, If a minimum of two out of four tines had engaged the myocardium, the device was released by cutting the tethering wire. The delivery tool and the sheath were removed, the access site was closed with a figure of 8 suture in two patients and with ProGlide (Abbott, Abbott Park, IL, USA) in 17 patients. All patients were ambulated immediately after the procedure and were observed overnight. The following morning, chest
x-ray and device interrogation were performed and the patient was discharged.
RESULTS
A total of 19 patients underwent leadless PM implantation with the jugular approach. Table 1 summarizes baseline characteristics, as well as implant data. There were nine female patients. The mean age was 77.5 ± 9.6 years. All patients had permanent AF with normal left ventricular ejection fraction >50%. Implant indication was AV conduction disturbance in 10 patients, pre-AV node ablation in seven patients, replacement of a conventional VVI system in two patients (infection in one and lead malfunction in the other). Eleven patients used new oral anticoagulants, whereas the other eight patients used vitamin K antagonists.
The device was positioned at the superior septum in seven patients, apicoseptal in seven patients, and midseptal in five patients. In 12 patients, a sufficient device position was obtained at the first attempt, in three at the second, in one at the third, in one at the fourth, and in two at the sixth attempt.
The mean pacing threshold was 0.56 ± 0.39 V at 0.24-ms pulse width, sensed amplitude was 9.1 ± 3.2 mV, mean fluoroscopy duration was 3.1 ± 1.6 min. There were no vascular or other complications. At follow-up, electrical parameters remained stable in 18 of 19 patients;
TA B L E 1 Baseline characteristics and implant data
Pt. no Age (years) Sex Implant indication OAC Attempts (n) Final position Sense (mV) Threshold (V) Tines (n) Fluoroscopy (min) attempts = number of attempted device deployments to reach final position; biplane system = duration of both fluoroscopes added; brady = bradycardia/atrioventricular conduction disturbances; fluoro = fluoroscopy duration in minutes; NOAC = new oral anticoagulants; OAC = oral anticoagulant usage; PM dysfunction = pacemaker dysfunction; pre-AVNA = pre-atrioventricular node ablation; Pt. no = patient number in order of implantation; sense = sensing value in millivolts; threshold = pacing threshold in volts, 0.24-ms pulse width; tines = number of tines engaging the myocardium as determined by pull and hold test; VKA = vitamin K antagonists.
in one patient a threshold rise occurred at 1 month, which was managed by increasing the pacing output.
DISCUSSION
To our knowledge, the jugular venous approach was reported previously in only one patient, who had an implanted inferior vena cava filter. 1 After the first two cases, where femoral approach was impossible or considered difficult, we decided to expand the usage of jugular approach to other patients. We now report a case series with 19 patients, in which the IJV approach was successful in all implantations. There were no vascular or other complications. Although a conventional pacing system may have been used, recent data showed leadless pacing systems to be associated with a lower complication rate, the main difference being caused by freedom of pocket related complications and infections. 3 Large-bore IJV cannulation has previously been shown to be safe for extracorporeal circulation. 4 The implantation procedure was relatively straightforward and uncomplicated.
Furthermore, the IJV approach may offer several advantages. For instance, septal sites were easier to reach. The septal site is nowadays a preferred site for lead insertion as Bongiorni et al showed long-term stability of nonapical pacing sites. 5 The jugular approach also avoids the His bundle and right bundle branch area, which may be safer in patients with left bundle branch block.
A potential source of concern is that the jugular route is straighter than the femoral route, potentially increasing the risk of inadvertent tip pressure. To avoid this, the delivery tool was kept in the flexed position and biplane fluoroscopy was used to ensure that the device was always positioned septally.
Finally, all patients could be ambulated immediately after the procedure allowing for a shorter hospital stay. Although experience is minimal, these data suggest that the internal jugular approach is safe and may be considered in patients where the femoral approach is impossible or considered undesirable.
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